<DOC>
	<DOCNO>NCT00863733</DOCNO>
	<brief_summary>This phase I study aim identify safe dos DMXAA patient solid tumor .</brief_summary>
	<brief_title>Study DMXAA ( Now Known ASA404 ) Solid Tumors</brief_title>
	<detailed_description>This dose escalation study conduct single center New Zealand . Patients receive dimethylxanthenone acetic acid ( DMXAA ) IV 20 minute every three week , maximum 12 course . Cohorts 3 patient receive escalated dos DMXAA maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 patient experience dose limit toxicity . Patients solid tumor standard therapy refractory conventional therapy .</detailed_description>
	<mesh_term>Vadimezan</mesh_term>
	<mesh_term>Retinol acetate</mesh_term>
	<criteria>1 . Histologically confirm solid tumor amenable standard therapy refractory conventional therapy 2 . Performance status WHO 02 3 . Life expectancy great 3 month 4 . Hemoglobin least 90 g/L ; WBC least 3,000/mm3 ; Platelet count least 100,000/mm3 5 . Bilirubin within normal limit ; ALT le 2 time upper limit normal ( ULN ) ; Alkaline phosphatase less 2 time ULN 6 . Creatinine le 130 umol/L 7 . INR APTT within normal limit 8 . Fertile patient must use effective contraception 9 . At least 4 week since prior anticancer therapy recover toxic effect 1 . Concurrent malignancy except cone biopsied carcinoma situ cervix adequately treat basal squamous cell carcinoma skin 2 . Other serious medical condition 3 . Uncontrolled infection serious infection within past 28 day 4 . Pregnant lactate 5 . Treatment glucocorticosteroids within previous two week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>